Research begins for LMG Life Sciences 2018
April 12, 2018
Legal Media Group has officially launched the 2018 LMG Life Sciences research cycle
US
Antitrust
| Antitrust-Highly recommended |
|---|
| Arnold & Porter |
| Cleary Gottlieb Steen & Hamilton |
| Covington & Burling |
| Dechert |
| Gibson, Dunn & Crutcher |
| Sidley Austin |
| Weil, Gotshal & Manges |
| White & Case |
| Antitrust-Recommended |
|---|
| Morgan Lewis & Bockius |
| Patterson Belknap Webb & Tyler |
| Ropes & Gray |
Corporate
| Corporate-Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Latham & Watkins |
| Morgan Lewis & Bockius |
| Ropes & Gray |
| Sidley Austin |
| Corporate-Recommended |
|---|
| Arnold & Porter |
| Covington & Burling |
| Dechert |
| Gibson, Dunn & Crutcher |
| Hogan Lovells |
| Jones Day |
| Morrison & Foerster |
| WilmerHale |
| Wilson Sonsini Goodrich & Rosati |
FDA: Medical Device
| FDA: Medical Devices-Highly Recommended |
|---|
| Hogan Lovells |
| Hyman Phelps & McNamara |
| King & Spalding |
| Sidley Austin |
| FDA: Medical Devices-Recommended |
|---|
| Arnold & Porter |
| Ropes & Gray |
FDA: Pharmaceutical
| FDA: Pharmaceutical-Highly Recommended |
|---|
| Covington & Burling |
| Hogan Lovells |
| Hyman Phelps & McNamara |
| Ropes & Gray |
| Sidley Austin |
| FDA: Pharmaceutical-Recommended |
|---|
| King & Spalding |
| Morgan Lewis & Bockius |
| Olsson Frank Weeda Terman Matz |
General Patent Litigation
Licensing & Collaboration
| Licensing & Collaboration-Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Hogan Lovells |
| Latham & Watkins |
| Morgan Lewis & Bockius |
| Ropes & Gray |
| WilmerHale |
| Wilson Sonsini Goodrich & Rosati |
| Licensing & Collaboration-Recommended |
|---|
| Covington & Burling |
| Dechert |
| Fenwick & West |
| Jones Day |
| Mintz Levin Cohn Ferris Glovsky and Popeo |
| Sidley Austin |
| Wiggin and Dana |
Mergers & Acquisitions
| Mergers & Acquisitions-Highly Recommended |
|---|
| Gibson, Dunn & Crutcher |
| Goodwin Procter |
| Latham & Watkins |
| Ropes & Gray |
| Sidley Austin |
| Mergers & Acquisitions-Recommended |
|---|
| Arnold & Porter |
| Cooley |
| Covington & Burling |
| Greenberg Traurig |
| Hogan Lovells |
| Morgan Lewis & Bockius |
| WilmerHale |
Patent Strategy & Management
Venture Capital
| Venture Capital-Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Latham & Watkins |
| Wilson Sonsini Goodrich & Rosati |
| Venture Capital-Recommended |
|---|
| Gunderson Dettmer |
| Hogan Lovells |
| Mintz Levin Cohn Ferris Glovsky and Popeo |
| Morgan Lewis & Bockius |
| Ropes & Gray |
| WilmerHale |
White-Collar/Govt. Investigations
| White-Collar/Government Investigation-Highly recommended |
|---|
| Cleary Gottlieb Steen & Hamilton |
| Covington & Burling |
| Gibson, Dunn & Crutcher |
| Hogan Lovells |
| King & Spalding |
| Morgan Lewis & Bockius |
| Ropes & Gray |
| Sidley Austin |
| White & Case |
| White-Collar/Government Investigation-Recommended |
|---|
| Arnold & Porter |
| Latham & Watkins |
| McDermott Will & Emery |
| Schulte Roth & Zabel |
| WilmerHale |
| Lawyer | Section | Practice Areas | Location |
|---|---|---|---|
| Bellomy, Mark | Finance & Transactional | Finance & Transactional | Boston |
| Brunts, Eve | Non-IP Litigation | Non-IP Litigation | Boston |
| Comeau, Christopher | Finance & Transactional | Finance & Transactional | Boston |
| Conry, Colleen | Non-IP Litigation | White-Collar/Govt. Investigations | Washington, D.C. |
| Levine, Gregory H | Regulatory | FDA: Pharmaceutical , FDA: Medical Device | Washington, D.C. |
| Levy, Joshua | Non-IP Litigation | White-Collar/Govt. Investigations | Boston |
| Liu, Joy | Regulatory | Regulatory | Washington, D.C. |
| McCaulley, Jr, Richard | Intellectual Property | Intellectual Property | Chicago |
| McPhee, Joan | Non-IP Litigation | White-Collar/Govt. Investigations | Boston |
| Mok, Arthur | Finance & Transactional | Finance & Transactional | |
| O'Connor, Brien | Non-IP Litigation | White-Collar/Govt. Investigations | Boston |
| Popofsky, Mark | Non-IP Litigation | Antitrust | Washington, D.C. |
| Prugo, Filko | Intellectual Property | Hatch-Waxman Patent Litigation (Branded) | New York City |
| Rubenstein, Marc A | Finance & Transactional | Corporate , Licensing & Collaboration , Venture Capital , Mergers & Acquisitions | Boston |
| Wilcox, Steven A | Finance & Transactional | Finance & Transactional | Boston |
| Zatylny, Marko | Finance & Transactional | Finance & Transactional | Boston |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Finance & Transactional
Ropes & Gray
Ropes & Gray offers one of the largest life sciences transactional practices in the country focusing on representing midsized to large life sciences companies. Clients include Goldman Sachs and JP Morgan, and some of the largest equity funds including TPG, Bain, Blackstone, and Sequoia Capital. Ropes also serves as lead counsel on many domestic and cross-border deals. One peer notes that "when Ropes gets a deal of a certain size, they are perfect."
The M&A team is particularly noteworthy, representing key client Pfizer in its $14 billion acquisition of Medivation. Christopher Comeau led the deal, and he represents public companies and middle-market financial investors in M&A and investment transactions. Clients include Shire, Johnson & Johnson, and Genzyme.
Steven Wilcox is founder and former chair of the firm's life sciences practice. He focuses on M&A, corporate financings, and licensing and collaborations in the biotech, medical device, and pharma spaces.
Marc Rubenstein represents clients in biotechnology, medical devices, and pharmaceuticals in licensing and collaboration, securities offerings, M&A, licensing and collaborations, supply and distribution agreements. Recently he led the firm in representing Vertex Pharmaceuticals in its $230 million licensing agreement with Merck KGaA that divests Vertex of its cancer drug pipeline.
Marko Zatylny represents investment banks and funds in M&A, corporate transactions, and corporate governance. Clients include Covidien and Pfizer.
Non-IP Litigation
A full-service firm, Ropes & Gray garners its most plentiful and vocal acknowledgement in the areas of investigations and antitrust. One peer confirms, "They brought in some people from Arnold & Porter to supplement the practice, and in litigation they are a very major player and a major competitor." Another offers, "Ropes & Gray as a whole are impressive in the life sciences, but, in particular their white-collar work for pharmaceutical companies has been exceptional."
Boston-based Brien O'Connor, a consistent peer mention and an attorney with extensive experience defending health care companies, officers, employees, pharmaceutical and medical device firms, was part of a Ropes & Gray government enforcement team that secured the dismissal of the entire qui tam whistleblower False Claims Act suit against client Stryker Corporation. The whistleblower, an orthopedic surgeon and former Stryker consultant, alleged that the client marketed pain pumps for potentially harmful off-label use, resulting in the submission of false claims to the government. The case was resolved in the client's favor in August 2014. O'Connor was also lead counsel for a pharmacy services provider in an investigation by DOJ and the US Attorney General's office in South Carolina of Omnicare and certain pharmaceutical manufacturers concerning contracts Omnicare had with those manufacturers, and acted as lead counsel in a qui tam action concerning Omnicare's alleged solicitation and receipt of kickbacks from a pharmaceutical manufacturer. Ropes & Gray negotiated a global settlement, which was executed in February 2014. Mark Popofsky represents Questcor Pharmaceuticals in defending an ongoing action brought by Retrophin arising out of Questcor's acquisition of the rights to the drug Synacthen, a synthetic adrenocorticotropic hormone approved for use only outside of the US, from Novartis AG. Retrophin claims that it attempted to buy the rights to Synacthen and that it planned to obtain FDA approval for Synacthen for indications served by Questcor's HP Acthar Gel.
Regulatory
Ropes & Gray
Ropes & Gray's team of Washington DC-based regulatory lawyers enjoys a stellar reputation for helping industry clients navigate complex FDA matters involving promotional questions, manufacturing, quality and safety, and a host of other compliance-related issues. The regulatory group possesses particularly deep experience in the pharmaceutical and medical device realms, a factor that is further enhanced by the firm's commitment to utilize, when necessary, the transactional and litigation attorneys who specialize in related life sciences industries.
Co-chair of the life sciences group, Gregory Levine, heads up the firm's regulatory group and focuses his own practice on life cycle compliance for leading pharmaceutical, medical device, and biotechnology clients. He also has significant experience counseling industry clients on compliance with health care fraud and abuse laws. Paul Rubin is another standout partner.